CNS/Brain Cancer
From the Journals
Dexamethasone may ‘jeopardize’ benefit of immunotherapy in glioblastoma
Baseline dexamethasone use was the strongest predictor of poor survival in glioblastoma patients receiving a checkpoint inhibitor.
Perspectives
COVID-19 vaccines and cancer patients: 4 things to know
From the Journals
Cancer rates on the rise in adolescents and young adults
Conference Coverage
Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest
Cancer patients treated with immune checkpoint inhibitors are not significantly more likely to develop or die from COVID-19, two studies suggest...
From the Journals
New findings on ‘exceptional responders’ to cancer therapies
Why do a small percentage of cancer patients show exceptional responses to therapy? The answer may lie in their genetic makeup.
Conference Coverage
Immunotherapy could fill unmet need in leptomeningeal metastases
More than a third of patients had a CNS response to systemically administered pembrolizumab, including two patients who had long-lived complete...
Clinical Insights
Using telehealth to deliver palliative care to cancer patients
Dr. Alan Lyss discusses the use of telehealth for palliative cancer care, including results from the REACH PC trial.
Conference Coverage
Molecular features of medulloblastoma may help personalize radiotherapy
The impact of different radiation-reducing strategies varied across four molecular subgroups.
Conference Coverage
SRS instead of WBRT for patients with multiple brain metastases
Feature
Are oncologists ready to confront a second wave of COVID-19?
Conference Coverage
Chemoradiation boosts glioblastoma survival in real-world setting